Nina Bach

Dr. Nina Bach


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2025 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
TRTill Reinhardt
Till Reinhardt
YHYassmine El Harraoui
Yassmine El Harraoui
ARAlex Rothemann
Alex Rothemann
AJAdrian T. Jauch
Adrian T. Jauch
SMSigrid Müller-Deubert
Sigrid Müller-Deubert
SSStephan A. Sieber
Stephan A. Sieber
Fluoroquinolones (FQs) are an important class of potent broad‐spectrum antibiotics. However, their general use is more and more limited by adverse side effects. While general mechanisms for the fluoroquinolone‐associated disability (FQAD) have been identified, the underlying molecular targets of toxicity remain elusive. In this study, focusing on the most commonly prescribed FQs Ciprofloxacin and Levofloxacin, whole proteome analyses revealed prominent mitochondrial dysfunction in human cells, specifically of the complexes I and IV of the electron transport chain (ETC). Furthermore, global untargeted chemo‐proteomic methodologies such as photo‐affinity profiling with FQ‐derived probes, as well as derivatization‐free thermal proteome profiling, were applied to elucidate human protein off‐targets of FQs in living cells. Accordingly, the interactions of FQs with mitochondrial AIFM1 and IDH2 have been identified and biochemically validated for their contribution to mitochondrial dysfunction. Of note, the FQ induced ETC dysfunction via AIFM1 activates the reverse carboxylation pathway of IDH2 for rescue, however, its simultaneous inhibition further enhances mitochondrial toxicity. This off‐target discovery study provides unique insights into FQ toxicity enabling the utilization of identified molecular principles for the design of a safer FQ generation.

29 August 2020 in Cells
Verified
Journal Article
Open access
PDF file
RLRutger D. Luteijn
Rutger D. Luteijn
PPPatrique Praest
Patrique Praest
FTFrank Thiele
Frank Thiele
SSSaravanan Manikam Sadasivam
Saravanan Manikam Sadasivam
KSKatrin Singethan
Katrin Singethan
EWEmmanuel J.H.J. Wiertz
Emmanuel J.H.J. Wiertz
The ongoing threat of viral infections and the emergence of antiviral drug resistance warrants a ceaseless search for new antiviral compounds. Broadly-inhibiting compounds that act on elements shared by many viruses are promising antiviral candidates. Here, we identify a peptide derived from the cowpox virus protein CPXV012 as a broad-spectrum antiviral peptide. We found that CPXV012 peptide hampers infection by a multitude of clinically and economically important enveloped viruses, including poxviruses, herpes simplex virus-1, hepatitis B virus, HIV-1, and Rift Valley fever virus. Infections with non-enveloped viruses such as Coxsackie B3 virus and adenovirus are not affected. The results furthermore suggest that viral particles are neutralized by direct interactions with CPXV012 peptide and that this cationic peptide may specifically bind to and disrupt membranes composed of the anionic phospholipid phosphatidylserine, an important component of many viral membranes. The combined results strongly suggest that CPXV012 peptide inhibits virus infections by direct interactions with phosphatidylserine in the viral envelope. These results reiterate the potential of cationic peptides as broadly-acting virus inhibitors.

29 November 2021 in Cells
Verified
Journal Article
Open access
PDF file
JKJana Key
Jana Key
STSylvia Torres-Odio
Sylvia Torres-Odio
NBNina Bach
Nina Bach
SGSuzana Gispert
Suzana Gispert
GKGabriele Koepf
Gabriele Koepf
GAGeorg Auburger
Georg Auburger
Biallelic pathogenic variants in CLPP, encoding mitochondrial matrix peptidase ClpP, cause a rare autosomal recessive condition, Perrault syndrome type 3 (PRLTS3). It is characterized by primary ovarian insufficiency and early sensorineural hearing loss, often associated with progressive neurological deficits. Mouse models showed that accumulations of (i) its main protein interactor, the substrate-selecting AAA+ ATPase ClpX, (ii) mitoribosomes, and (iii) mtDNA nucleoids are the main cellular consequences of ClpP absence. However, the sequence of these events and their validity in human remain unclear. Here, we studied global proteome profiles to define ClpP substrates among mitochondrial ClpX interactors, which accumulated consistently in ClpP-null mouse embryonal fibroblasts and brains. Validation work included novel ClpP-mutant patient fibroblast proteomics. ClpX co-accumulated in mitochondria with the nucleoid component POLDIP2, the mitochondrial poly(A) mRNA granule element LRPPRC, and tRNA processing factor GFM1 (in mouse, also GRSF1). Only in mouse did accumulated ClpX, GFM1, and GRSF1 appear in nuclear fractions. Mitoribosomal accumulation was minor. Consistent accumulations in murine and human fibroblasts also affected multimerizing factors not known as ClpX interactors, namely, OAT, ASS1, ACADVL, STOM, PRDX3, PC, MUT, ALDH2, PMPCB, UQCRC2, and ACADSB, but the impact on downstream metabolites was marginal. Our data demonstrate the primary impact of ClpXP on the assembly of proteins with nucleic acids and show nucleoid enlargement in human as a key consequence.

6 November 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
DHDorothea Höpfner
Dorothea Höpfner
ACAdam Cichy
Adam Cichy
VPVivian Pogenberg
Vivian Pogenberg
CKChristoph Krisp
Christoph Krisp
SMSoraya Mezouar
Soraya Mezouar
AIAymelt Itzen
Aymelt Itzen
The intracellular bacterial pathogen Coxiella burnetii evades the host response by secreting effector proteins that aid in establishing a replication-friendly niche. Bacterial filamentation induced by cyclic AMP (Fic) enzymes can act as effectors by covalently modifying target proteins with the posttranslational AMPylation by transferring adenosine monophosphate (AMP) from adenosine triphosphate (ATP) to a hydroxyl-containing side chain. Here we identify the gene product of C. burnetii CBU_0822, termed C. burnetii Fic 2 (CbFic2), to AMPylate host cell histone H3 at serine 10 and serine 28. We show that CbFic2 acts as a bifunctional enzyme, both capable of AMPylation as well as deAMPylation, and is regulated by the binding of DNA via a C-terminal helix-turn-helix domain. We propose that CbFic2 performs AMPylation in its monomeric state, switching to a deAMPylating dimer upon DNA binding. This study unveils reversible histone modification by a specific enzyme of a pathogenic bacterium.

25 October 2024 in ACS Omega
Verified
Journal Article
Open access
EDEleonora Diamanti
Eleonora Diamanti
ASAnnina Steinbach
Annina Steinbach
LCLais Pessanha De Carvalho
Lais Pessanha De Carvalho
HRHenni-Karoliina Ropponen
Henni-Karoliina Ropponen
ALAntoine Lacour
Antoine Lacour
AHAnna Hirsch
Anna Hirsch
The enzyme IspE in Plasmodium falciparum is considered an attractive drug target, as it is essential for parasite survival and is absent in the human proteome. Yet it still has not been addressed by a small-molecule inhibitor. In this study, we conducted a high-throughput screening campaign against the PfIspE enzyme. Our approach toward a PfIspE inhibitor comprises in vitro screening, structure-activity relationship studies, examining the docking position using an AlphaFold model, and finally target verification through probe binding and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis. The newly synthesized probe containing a diazirine and an alkyne moiety (23) allowed us to demonstrate its binding to IspE in the presence of a lysate of human cells (HEK293 cells) and to get evidence that both probe 23 and the best inhibitor of the series (19) compete for the same IspE binding site.

1 October 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
PKPavel Kielkowski
Pavel Kielkowski
IBIsabel Y. Buchsbaum
Isabel Y. Buchsbaum
VKVolker C. Kirsch
Volker C. Kirsch
NBNina Bach
Nina Bach
MDMicha Drukker
Micha Drukker
SSStephan A. Sieber
Stephan A. Sieber
Posttranslational modification (PTM) of proteins represents an important cellular mechanism for controlling diverse functions such as signalling, localisation or protein-protein interactions 1 . AMPylation (also termed adenylylation) has recently been discovered as a prevalent PTM for regulating protein activity 2 . In human cells AMPylation has been exclusively studied with the FICD protein 3–6 . Here we investigate the role of AMPylation in human neurogenesis by introducing a cell-permeable propargyl adenosine pronucleotide probe to infiltrate cellular AMPylation pathways and report distinct modifications in intact cancer cell lines, human-derived stem cells, neural progenitor cells (NPCs), neurons and cerebral organoids (COs) via LC-MS/MS as well as imaging methods. A total of 162 AMP modified proteins were identified. FICD-dependent AMPylation remodelling accelerates differentiation of neural progenitor cells into mature neurons in COs, demonstrating a so far unknown trigger of human neurogenesis.